Abstract: Molecules comprising the antigen-binding portion of antibodies that block constitutive and/or ligand-dependent activation of a receptor protein tyrosine kinase, such as fibroblast growth factor receptor 3 (FGFR3), are found through screening methods, where a soluble dimeric form of a receptor protein tyrosine kinase is used as target for screening a library of antibody fragments displayed on the surface of bacteriophage. The molecules of the present invention which block constitutive activation can be administered to treat or inhibit skeletal dysplasia, craniosynostosis disorders, cell proliferative diseases or disorders, or tumor progression associated with the constitutive activation of a receptor protein tyrosine kinase.
Type:
Grant
Filed:
February 27, 2009
Date of Patent:
September 9, 2014
Assignee:
Fibron Limited
Inventors:
Avner Yayon, Eran Rom, Elisabeth Thomassen-Wolf, Eric Borges
Abstract: Molecules comprising the antigen-binding portion of antibodies that block constitutive and/or ligand-dependent activation of a receptor protein tyrosine kinase, such as fibroblast growth factor receptor 3 (FGFR3), are found through screening methods, where a soluble dimeric form of a receptor protein tyrosine kinase is used as target for screening a library of antibody fragments displayed on the surface of bacteriophage. The molecules of the present invention which block constitutive activation can be administered to treat or inhibit skeletal dysplasia, craniosynostosis disorders, cell proliferative diseases or disorders, or tumor progression associated with the constitutive activation of a receptor protein tyrosine kinase.
Type:
Grant
Filed:
December 15, 2003
Date of Patent:
March 3, 2009
Assignee:
Fibron Limited
Inventors:
Avner Yayon, Eran Rom, Elisabeth Thomassen-Wolf, Eric Borges
© 2024 Justia
